All In Biotech

Drug Trial Radar · NCT00828737

Safety of Gadovist in Renally Impaired Patients

Prospective Non-randomized (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Gadovist in Patients With Moderate to Severe Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information

Last checked: Nov 19, 2026Latest source record: Feb 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

927

Actual

Start

Dec 2008

Primary completion

Jan 2015

Study completion Jan 2015

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jan 26, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Gadovist, will be asked to participate. The administration of contrast agents that contain gadolinium such as Gadovist might increase a potential risk to develop a rare condition called nephrogenic systemic fibrosis (NSF) in patients with renal impairment. This study is to assess the potential risk to develop NSF in patients with renal impairment after the administration of Gadovist. Patients who are enrolled in this study will receive a Gadovist enhanced MRI scan which was prescribed by the referring doctor. After the MRI scan the patient will be included in a two year follow-up period to assess if signs or symptoms suggestive of NSF have appeared.

Conditions

  • Fibrosis
  • Renal Impairment

Interventions

  • Gadobutrol (Gadovist, BAY86-4875)Drug

    Gadovist in approved indications at approved dosages

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with moderate to severe renal impairment, who develop Nephrogenic Systemic Fibrosis (NSF), based on diagnostically specific clinical and histopathological informationTime frame: From the time of MRI until the end of follow-up period (24 months)

Locations

70 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Westmead NSW, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Clayton, Victoria, Australia

  • Site not named

    Geelong, Victoria, Australia

  • Site not named

    Ehenbichl, Austria

  • Site not named

    Graz, Austria

  • Site not named

    Leoben, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Innsbruck, Tyrol, Austria

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Fleurimont, Quebec, Canada

  • Site not named

    Le Kremlin-Bicêtre, France

  • Site not named

    Lille, France

  • Site not named

    Marseille, France

  • Site not named

    Paris, France

  • Site not named

    Reims, France

  • Site not named

    Mannheim, Baden-Wurttemberg, Germany

  • Site not named

    Tübingen, Baden-Wurttemberg, Germany

  • Site not named

    Coburg, Bavaria, Germany

  • Site not named

    Erlangen, Bavaria, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Regensburg, Bavaria, Germany

  • Site not named

    Neuruppin, Brandenburg, Germany

  • Site not named

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • Site not named

    Frankfurt am Main, Hesse, Germany

  • Site not named

    Hannoversch Münden, Lower Saxony, Germany

  • Site not named

    Osnabrück, Lower Saxony, Germany

  • Site not named

    Dortmund, North Rhine-Westphalia, Germany

  • Site not named

    Essen, North Rhine-Westphalia, Germany

  • Site not named

    Lüdenscheid, North Rhine-Westphalia, Germany

  • Site not named

    Dresden, Saxony, Germany

  • Site not named

    Leipzig, Saxony, Germany

  • Site not named

    Magdeburg, Saxony-Anhalt, Germany

  • Site not named

    Berlin, State of Berlin, Germany

  • Site not named

    Berlin, State of Berlin, Germany

  • Site not named

    Gera, Thuringia, Germany

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.